Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 80

Sort by

Sort Order Select

Journal Articles

Reducing the Burden of Chemoradiotherapy with the Combination of Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Jessica C. Hochberg, MD, Jaclyn Basso, RN, MSN, PNP, Liana Klejmont, Pharm D, Lauren Harrison, RN, MSN, Allyson M. Flower, MD, Aliza Gardenswartz, MD, Qiuhu Shi, PhD, Perry Gerard, MD MBA, FACR, Humayan Islam, MD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 127.

https://doi.org/10.1182/blood-2019-128684

Published: 2019

Journal Articles

A Randomized Evaluation of Vinorelbine Versus Gemcitabine Chemotherapy Mobilization of Stem Cells in Myeloma Patients

Barbara Jeker, Sarah Farag, Urban Novak, Ulrike Bacher, Behrouz Mansouri Taleghani, Qiyu Li, Thomas Pabst, MD

Blood (2019) 134 (Supplement_1): 1963.

https://doi.org/10.1182/blood-2019-127848

Published: 2019

Journal Articles

Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents

R. Alejandro Sica, MD, Michael A Spinner, John S Tamaresis, PhD, Ranjana H Advani, MD, Laura J Johnston, MD, Robert Lowsky, MD, Everett H Meyer, MD PhD, David B Miklos, MD PhD, Lori S Muffly, MD, Andrew R Rezvani, MD, Judith A Shizuru, MD PhD, Wen-Kai Weng, MD PhD, Robert S. Negrin, MD, Sally Arai, MD

Blood (2019) 134 (Supplement_1): 2022.

https://doi.org/10.1182/blood-2019-131532

Published: 2019

Journal Articles

Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma

Alison J. Moskowitz, MD, Heiko Schoder, MD, Jisun Lee, Theresa Davey, MMSc, PA-C, Helen Hancock, ANP, Paul A. Hamlin, MD, Steven M. Horwitz, MD, Anita Kumar, MD, Matthew J Matasar, MD, Ariela Noy, MD, M. Lia Palomba, MD, Gunjan L. Shah, MDMS, Miguel-Angel Perales, MD, Craig S. Sauter, MD, David J. Straus, MD, Anas Younes, MD, Andrew D. Zelenetz, MD PhD, Joachim Yahalom, MD, Craig H. Moskowitz

Blood (2019) 134 (Supplement_1): 1555.

https://doi.org/10.1182/blood-2019-129364

Published: 2019

Journal Articles

BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression

Paul J. Hampel, MD, Timothy G. Call, MD, Sara J. Achenbach, Kari G Rabe, Wei Ding, MD PhD, Eli Muchtar, MD, Saad S. Kenderian, MD, Yucai Wang, MD PhD, Amber Koehler, PA-C, MS, Amie Fonder, PA-C, MS, Jose F. Leis, MD PhD, Susan M. Schwager, Daniel L. Van Dyke, PhD, Esteban Braggio, PhD, Susan L. Slager, PhD, Neil E. Kay, MD, Sameer A. Parikh, MD

Blood (2019) 134 (Supplement_1): 3050.

https://doi.org/10.1182/blood-2019-125411

Published: 2019

Journal Articles

High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed and Refractory Classical Hodgkin Lymphoma

Blood (2019) 134 (Supplement_1): 2837.

https://doi.org/10.1182/blood-2019-127575

Published: 2019

Journal Articles

Efficacy and Safety of PD-1 Inhibitor Plus GVD Chemotherapy in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (rrPMLBCL)

Qian Mei, PhD, Wenying Zhang, MD, Yang Liu, MD, Qingming Yang, MD, John E.J. Rasko, MBBS, PhD, Weidong Han, PhD MD

Blood (2019) 134 (Supplement_1): 4072.

https://doi.org/10.1182/blood-2019-121768

Published: 2019

Journal Articles

Clofarabine with Topotecan, Vinorelbine, and Thiotepa (TVTC) in Children and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia

Kavitha Ramaswamy, MD, Christopher Forlenza, MD, Rachel Kobos, MD, Peter G. Steinherz, MD, Neerav Shukla, MD

Blood (2018) 132 (Supplement 1): 79.

https://doi.org/10.1182/blood-2018-99-115185

Published: 2018

Journal Articles

Vinorelbine-Based Hematopoietic Stem-Cell Mobilization: A More Effective, Low-Cost Alternative to Conventional Chemotherapy

Bruno Kosa Lino Duarte, MD, Marcos Paulo Colella, MD MSc, Fernando Vieira Pericole Souza, MD PhD, Gabriela G Yamaguti-Hayakawa, MD, Jose Francisco Comenalli Marques, Jr., MD PhD, Afonso Celso Vigorito, MD PhD, Erich Vinicius De Paula, MD PhD, Margareth C Ozelo, MD PhD

Blood (2018) 132 (Supplement 1): 4762.

https://doi.org/10.1182/blood-2018-99-119884

Published: 2018

Journal Articles

Hematopoietic Stem Cell Transplant Utilization in Relapsed/Refractory Hodgkin Lymphoma: A Population Level Analysis of Statewide Claims Data

Anem Waheed, MD MPH, Angie Mae Rodday, PhD MS, Anita J Kumar, MD MS, Kenneth B. Miller, MD, Susan K Parsons, MD MRP

Blood (2018) 132 (Supplement 1): 4771.

https://doi.org/10.1182/blood-2018-99-111921

Published: 2018

Journal Articles

Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients

Neha Mehta-Shah, Nancy L. Bartlett

Blood (2018) 131 (15): 1698–1703.

https://doi.org/10.1182/blood-2017-09-772681

Published: 2018

Journal Articles

Efficacy of Chemotherapy or Chemo-Anti-PD-1 Combination after Unsatisfactory Response of Anti-PD-1 Therapy for Relapsed and Refractory Hodgkin Lymphoma: A Retrospective Series from Lysa Centers

Blood (2017) 130 (Supplement 1): 652.

https://doi.org/10.1182/blood.V130.Suppl_1.652.652

Published: 2017

Journal Articles

Monitoring MRD Guided Treatment Outcome of Adult Patients with Acute Lymphoblastic Leukemia Using ALL-BFM95 Based Protocol

Stephen Yang Liang, MD

Blood (2017) 130 (Supplement 1): 5040.

https://doi.org/10.1182/blood.V130.Suppl_1.5040.5040

Published: 2017

Journal Articles

Clinical Profiles, Treatment Characteristics and Outcomes Among Newly Diagnosed Hodgkin Lymphoma Patients Presenting with Unfavorable and Advanced Disease within a US Community Oncology Setting

Christopher A. Yasenchak, MD, Joseph Feliciano, PharmD, Kathleen M. Aguilar, MPH, Jamyia Clark, MPH, E Susan Amirian, PhD MS, Akshara Richhariya, PhD

Blood (2017) 130 (Supplement 1): 5177.

https://doi.org/10.1182/blood.V130.Suppl_1.5177.5177

Published: 2017

Journal Articles

Bvgp: A Novel Protocol for Hodgkin's with Excellent Response, Minimal Acute Toxicities and Reduced Risk of Late Effects

Bruce Bostrom, MD, Nathan Gossai, MD, Joanna Lee Perkins, MPH, MD, Michael Richards, MD PhD, Yoav H. Messinger, MD

Blood (2017) 130 (Supplement 1): 5192.

https://doi.org/10.1182/blood.V130.Suppl_1.5192.5192

Published: 2017

Journal Articles

Upfront Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Jessica C. Hochberg, MD, Liana Klejmont, Pharm D, Lauren Harrison, RN, MSN, Allyson M. Flower, MD, Quihu Shi, PhD, Jaclyn Basso, RN, MSN, PNP, Mitchell S. Cairo, MD

Blood (2017) 130 (Supplement 1): 4094.

https://doi.org/10.1182/blood.V130.Suppl_1.4094.4094

Published: 2017

Journal Articles

Comparative Effectiveness of High-Dose Bendamustine-EAM Versus BEAM in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation

Erica Tsang, Diego Villa, MD, Federica Loscocco, Alina S Gerrie, MD, Giuseppe Visani, Maryse Power, MB, Barbara Guiducci, Cristina Clissa, MD PhD, Joseph M Connors, MD, Kerry J Savage, BSc, MD MSc, Kevin W Song, MD, Cindy Toze, Yasser Abou-Mourad, Heather Sutherland, MD, David Sanford, MD, Stephen H Nantel, MD, Laurie H. Sehn, MDMPH, David W. Scott, MD PhD FRACP, FRCPA, Alessandro Isidori, MD PhD

Blood (2017) 130 (Supplement 1): 3291.

https://doi.org/10.1182/blood.V130.Suppl_1.3291.3291

Published: 2017

Journal Articles

Synergistic Lethality with Gemcitabine and Arsenic Trioxide Against Human T Cell Lymphoma Jurkat Cells

Mingwan Zhang, MD, Xiaojun Xu, MD PhD, Yongbin Ye, MD PhD, Qifa Liu

Blood (2016) 128 (22): 5383.

https://doi.org/10.1182/blood.V128.22.5383.5383

Published: 2016

Journal Articles

Efficacy of Brentuximab-Vedotin (BV) in Peripheral T-Cell Lymphomas (PTCLs) Other Than Anaplastic Large Cell Lymphoma (ALCL)

Cristina Zannori, MD, Roberta Martiniani, MD, Stefano Ascani, MD, Fabrizio Liberati, MD, Annamaria Rauco, MD, Angelo Genua, MD, Anna Marina Liberati, MD

Blood (2016) 128 (22): 5364.

https://doi.org/10.1182/blood.V128.22.5364.5364

Published: 2016

Journal Articles

Effect of the CEP72 Genotype and CYP3A5-Mediated Metabolism in Predicting Vincristine-Associated Peripheral Neuropathy

Vaibhav Agrawal, MD, M.B.A., Diane T. Smelser, PhD, David J. Carey, PhD, Joseph J. Vadakara, MD, Sharif S. Khan, MD

Blood (2016) 128 (22): 5963.

https://doi.org/10.1182/blood.V128.22.5963.5963

Published: 2016

NARROW

Reducing the Burden of Chemoradiotherapy with the Combination of Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

A Randomized Evaluation of Vinorelbine Versus Gemcitabine Chemotherapy Mobilization of Stem Cells in Myeloma Patients

Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents

Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma

BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression

High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed and Refractory Classical Hodgkin Lymphoma

Efficacy and Safety of PD-1 Inhibitor Plus GVD Chemotherapy in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (rrPMLBCL)

Clofarabine with Topotecan, Vinorelbine, and Thiotepa (TVTC) in Children and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia

Vinorelbine-Based Hematopoietic Stem-Cell Mobilization: A More Effective, Low-Cost Alternative to Conventional Chemotherapy

Hematopoietic Stem Cell Transplant Utilization in Relapsed/Refractory Hodgkin Lymphoma: A Population Level Analysis of Statewide Claims Data

Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients

Efficacy of Chemotherapy or Chemo-Anti-PD-1 Combination after Unsatisfactory Response of Anti-PD-1 Therapy for Relapsed and Refractory Hodgkin Lymphoma: A Retrospective Series from Lysa Centers

Monitoring MRD Guided Treatment Outcome of Adult Patients with Acute Lymphoblastic Leukemia Using ALL-BFM95 Based Protocol

Clinical Profiles, Treatment Characteristics and Outcomes Among Newly Diagnosed Hodgkin Lymphoma Patients Presenting with Unfavorable and Advanced Disease within a US Community Oncology Setting

Bvgp: A Novel Protocol for Hodgkin's with Excellent Response, Minimal Acute Toxicities and Reduced Risk of Late Effects

Upfront Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Comparative Effectiveness of High-Dose Bendamustine-EAM Versus BEAM in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation

Synergistic Lethality with Gemcitabine and Arsenic Trioxide Against Human T Cell Lymphoma Jurkat Cells

Efficacy of Brentuximab-Vedotin (BV) in Peripheral T-Cell Lymphomas (PTCLs) Other Than Anaplastic Large Cell Lymphoma (ALCL)

Effect of the CEP72 Genotype and CYP3A5-Mediated Metabolism in Predicting Vincristine-Associated Peripheral Neuropathy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only